Loading clinical trials...
Loading clinical trials...
Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA
Conditions
Interventions
Entecavir
Lamivudine
Locations
2
South Korea
Pusan National University School of Medicine
Busan, Busan, South Korea
Severance Hospital
Seoul, Seoul, South Korea
Start Date
February 1, 2008
Primary Completion Date
November 1, 2010
Completion Date
November 1, 2010
Last Updated
March 5, 2015
NCT04166266
NCT06550622
NCT05922306
NCT05870969
NCT04856085
NCT04780204
Lead Sponsor
Pusan National University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions